Lindsay Goldberg to buy Bilcare Research in a deal worth USD 279-334 million: Report
Bilcare Research, which employs 1000 staff and has annual sales of 300 million euros, produces plastic packaging used in the pharmaceutical, consumer goods and chip card manufacturing industries.
Frankfurt: Private equity investor Lindsay Goldberg has agreed to buy Bilcare Research, in a deal valuing the Swiss pharma packaging group at 250-300 million euros ($279-334 mln), including debt, two people close to the matter said.
Bilcare Research, which employs 1000 staff and has annual sales of 300 million euros, produces plastic packaging used in the pharmaceutical, consumer goods and chip card manufacturing industries.
Read Also: OxyContin maker Purdue Pharma agrees to provide proprietary research, other data
Lindsay Goldberg, which has investments in other packaging groups - Weener, Schur Flexibles und Paccor - declined to comment. Bilcare also declined to comment.
Bilcare's customers include Novartis, GlaxoSmithKline and Pfizer, according to the company's website.
Read Also: Gilead licenses respiratory, herpes antiviral research programs from Novartis
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd